We Chelsea about That . . .
Phase III Endpoint Switcheroo: Proceed at Your (Lesser?) Risk
By Randy Osborne
Monday, November 9, 2009
Chelsea Therapeutics Inc.'s earnings-call news last week that the firm is asking the FDA to allow an endpoint change in the still-blinded, second Phase III test with droxidopa for low blood pressure caused some Wall Street ripples, and sparked speculation on the wisdom of such a move.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.